Menu
Close
.svg)
A few weeks ago, during a conversation with a group of clients at their advertising agency, I brought up a concept that caught many of them off guard: dosing symmetry. Few in the room had heard of it before. For me, though, it’s an old concept I learned years ago while working on HIV treatments -- one that still carries relevance today. In fact, I’d argue it’s a concept worth resurfacing and passing along to those who are newer to pharma marketing.
So what is dosing symmetry? Put simply, it’s the idea that patients are more likely to adopt a new therapy if its dosing schedule matches the habits they already have. A patient accustomed to taking one pill once a day (QD) finds it easier to add another QD therapy. Similarly, someone already taking a twice-daily (BID) medication will more easily add another BID medication. The converse is also true: asking a QD patient to shift to BID might feel disruptive. And further -- if someone in the habit of taking QD and/or BID medications is asked to add a long-acting treatment, for example a weekly oral treatment, it potentially could lead to adherence challenges.
Patients rarely start fresh when a new prescription comes along. Their perception of convenience is filtered through age, years of routines, and lifestyle.
For older adults, polypharmacy is common. Many already have BID therapies in their pillboxes: examples might include metformin for diabetes, carvedilol for hypertension or heart failure, gabapentin for neuropathic pain, or levetiracetam for seizure disorders. In these cases, adding another BID drug might be considered "behaviorally congruent" -- it doesn’t disrupt the cadence of daily life.
For younger patients, however, the story looks very different. A 35-year-old with no existing prescriptions has no anchor habit. For them, even QD can feel like a hurdle. In fact, younger patients often prefer less frequent regimens -- such as once-weekly GLP-1 agonists for diabetes...or osteoporosis treatments administered less than once a day -- because they want therapy to intrude less into their lifestyle.
The key, then, is understanding how dosing symmetry plays out differently across patient groups -- and tailoring the story accordingly.
Years ago, I worked on an HIV therapy competing against once-daily options. On paper, BID dosing seemed to be a liability. The consensus among HIV-treating HCPs was: “I prefer to prescribe QD. It’s easier for my patients.”
But deeper conversations revealed a more nuanced truth -- and an opportunity. Many patients were already on BID regimens, whether for opportunistic infection prophylaxis, pain management, or other chronic conditions. For these individuals, adding one more BID pill wasn’t a major hurdle. By reframing BID as consistent with patients’ lived routines, we helped physicians see that adherence could remain strong even with a BID regimen.
What at first looked like a disadvantage became a reassurance -- something that de-risked the prescribing decision. Indeed, before long, doctors were repeating the phrase "dosing symmetry" back to us in marketing research interviews.
Dosing symmetry offers three practical takeaways for commercial and insights leaders:
The principle extends beyond HIV. Cardiovascular, diabetes, neurology, psychiatry, and infectious disease treatments all vary in dosing. If we frame therapies in ways that acknowledge patients’ lived routines, we can not only optimize uptake but also mitigate adherence challenges that often derail real-world outcomes.
Medications don’t succeed in the clinic alone -- they succeed when they fit into lives. Dosing symmetry reminds us that lifestyle alignment is not a “nice to have”; it’s central to impact. For pharma marketers, leveraging this behavioral insight isn’t just smart messaging. It’s a way to enable better health, establish better habits and promote better outcomes.
